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1. Introduction 
Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer, the fifth 
most common type of solid tumor, and the third highest cause of cancer mortality 
worldwide (Parkin et al., 2005, Motola-Kuba et al., 2006). On the other hand, nonalcoholic 
fatty liver disease (NAFLD) is now recognized as one of the most common liver disorders 
(Lazo and Clark, 2008). The subclinical nature of this disease has prompted research to 
improve its diagnosis and prevent its progression to nonalcoholic steatohepatitis (NASH), 
liver cirrhosis, and HCC. An increasing number of reports indicate that NAFLD is the key 
link between obesity and HCC (Chavez-Tapia et al., 2009, Mendez-Sanchez et al., 2007). It 
has been suggested that most cases of HCC involve progression of NASH to cirrhosis 
(Caldwell et al., 2004). In 1980, Ludwig et al. described NASH as an advanced form of fatty 
liver disease. They defined it as a well-recognized clinical pathological syndrome that occurs 
primarily in obese women with diabetes mellitus and has histological similarities to 
alcoholic liver disease in the absence of heavy alcohol consumption (Ludwig et al., 1980). 
Some reports suggest that 10–24% of the populations of various countries have NAFLD. The 
prevalence of NAFLD is higher among obese and diabetic patients (70–86%). NASH is 
estimated to occur in 10% of NAFLD patients. NASH has been posited as a possible cause of 
cryptogenic cirrhosis (CC) (Bellentani et al., 2000). Patients with CC also develop HCC 
(Caldwell et al., 1999). In this review, we discuss the associations between obesity and 
cancer, between metabolic syndrome and NAFLD, and between NAFLD and HCC. 
2. Obesity and cancer 
The World Health Organization defines obesity as fat accumulation in adipose tissue to the 
extent that health is impaired. For epidemiological purposes, overweight is defined as a body 
mass index (BMI) greater than 25 kg/m2 and obesity is defined as a BMI greater than 30 kg/m2. 
Epidemiological studies provide convincing evidence of an association between obesity and 
cancer of the esophagus (adenocarcinoma), pancreas, colorectum, breast (postmenopausal), 
endometrium, and kidney (WCR, 2007). The largest meta-analysis to date involved 282,000 
patients from prospective observational studies and more than 133 million person-years of 
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follow-up. It showed that a high BMI is associated with a high incidence of cancer. The 
association is modest and risk estimates range from 1.1 to 1.6 for an increase in BMI of 5 
kg/m2. For people with an average BMI (23 kg/m2), a 5 kg/m2 increase in BMI corresponds 
to a weight gain of 15 kg (men) or 13 kg (women). The associations between obesity and 
cancer are sex and site specific but are broadly consistent across geographic populations 
(Renehan et al., 2008). Emerging evidence suggests that weight loss after bariatric surgery 
reduces the incidence of cancer (Sjostrom et al., 2009). Furthermore, a prospective study of 
900,000 adults in the United States showed that obesity accounts for 14% of all deaths from 
cancer in men and for 20% of all deaths from cancer in women (Calle et al., 2003) (Fig.1). 
Men and women with a BMI greater than 40 kg/m2 have death rates 52% and 62%, 
respectively, higher than those of people with normal BMIs. This indicates that obesity also 
affects the outcome of cancer and this finding is supported by studies showing increased 
perioperative mortality rates for obese people (Li et al., 2009, Meyerhardt et al., 2003, 
Haydon et al., 2006, Dignam et al., 2006). There appears to a sex differential with respect to 
the risk of developing cancer: men have a higher risk than women of developing cancer 
when their BMI is elevated (Renehan et al., 2008, Moore et al., 2004). This may be due to 
hormonal differences or it may indicate that BMI is a poor index of central adiposity in 
females. As females generally only deposit adipose tissue centrally when the total volume of 
deposited fat is elevated, overweight BMIs do not correspond with visceral fat volume in 
females to the same extent as in males, which may account for the differences in cancer risk 
observed when BMI is used to determine obesity status. 
 
Fig. 1. Mortality from cancer in obese men in the USA. 
The highest relative risk was observed in liver cancer. It is also important to note that 
gastrointestinal tumors are associated with the highest relative risk of death according to 
BMI and obesity. 
In studies in which measures of visceral adiposity such as waist circumference (WC) or 
visceral fat adiposity (VFA) were used, visceral adiposity was associated with an increased 
risk of cancer (Moore et al., 2004, Wang et al., 2008, Steffen et al., 2009); it is a stronger 
predictor of cancer than BMI (Moore et al., 2004), and the cancer risk is similar for males and 
females (Moore et al., 2004, Wang et al., 2008). Large-scale studies on visceral adiposity 
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across cancer sites are needed to clarify whether there is a clear differential effect of visceral 
versus subcutaneous obesity. Visceral adiposity (and not subcutaneous adiposity) is 
associated with development of features of metabolic syndrome (a proxy for a 
dysmetabolic profile in viscerally obese patients) (Donohoe et al., 2010). Most of the 
components of the syndrome, alone (Cowey and Hardy, 2006, Giovannucci, 2007) or in 
combination (Colangelo et al., 2002, Bowers et al., 2006, Trevisan et al., 2001), have been 
individually linked to cancer at various sites. A prospective international population-
based study of 580,000 people (the Me-Can Study) is under way to identify whether 
metabolic syndrome is independently associated with cancer. Initial findings suggest that 
a combination of components of metabolic syndrome is associated with colorectal cancer 
(men RR, 1.25 [95% CI, 1.18–1.32]; women RR, 1.14 [95% CI, 1.02–1.18]) (Stocks et al., 
2010), endometrial cancer (RR, 1.37; [95% CI, 1.28–1.46]) (Bjorge et al., 2010), bladder 
cancer in men (RR, 1.1; [95% CI, 1.01–1.18]) (Stocks et al., 2010), and pancreatic cancer in 
women (RR, 1.58; [95% CI, 1.34–1.87])(Johansen et al., 2010). 
3. Metabolic syndrome and NAFLD 
Metabolic syndrome is a condition characterized by a cluster of symptoms, including 
glucose intolerance/insulin resistance, abdominal obesity, atherogenic dysfunction, 
dyslipidemia (low concentrations of high-density lipoprotein cholesterol and high 
concentrations of triglycerides), elevated blood pressure, a proinflammatory state, and a 
prothrombotic state. It increases morbidity and mortality, especially in respect of 
cardiovascular disease (Reaven, 2002, Grundy et al., 2004). NAFLD can be considered the 
hepatic manifestation of metabolic syndrome (Fig. 2) (Rector et al., 2008). NAFLD is strongly 
associated with metabolic syndrome; 90% of patients with NAFLD have more than one 
feature of metabolic syndrome and 33% have three or more features (Marchesini et al., 2003). 
Furthermore, the risk of steatosis increases exponentially as the number of components of 
metabolic syndrome increases (Marceau et al., 1999). NAFLD has been consistently 
associated with obesity (60–95%), type 2 diabetes (28–55%), and dyslipidemia (27–92%) 
(Bugianesi et al., 2005). Metabolic syndrome is associated with liver disease, which may 
progress and become severe. In addition, the likelihood of developing NASH increases with  
 
Fig. 2. Triglyceride synthesis and NAFLD. 
Triglyceride synthesis increases in states of energy excess. Insulin resistance and 
hyperinsulinemia increase lipolysis of triglyceride depots in adipose tissue, amplifying the 
delivery of free fatty acids Free Fatty Acids (FFA) to the liver. Insulin further stimulates liver 
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the severity of obesity (Bugianesi et al., 2005, Marchesini et al., 2003). There is a universal 
association between NASH and insulin resistance regardless of BMI, suggesting that insulin 
resistance is a central factor in the pathogenesis of NASH (Chitturi et al., 2002). The elevated 
expression of tumor necrosis factor-alpha (TNF-) in the liver observed in NAFLD may  
represent a link between insulin resistance and hepatic steatosis. TNF- has been proposed 
as an important component of peripheral insulin resistance in obesity and type 2 diabetes. It 
is linked to increased oxidative stress and cell death in the liver, and potentiates the 
development of liver fibrosis and progression to NASH (Jiang and Torok, 2008). 
4. NAFLD and HCC 
It is clear that cirrhosis is linked to the development of HCC regardless of the underlying 
etiology of liver disease. The exact mechanism responsible for the development of HCC in 
NASH remains unclear, although the pathophysiological mechanisms responsible for the 
development of NASH associated with insulin resistance and the subsequent inflammatory 
cascade likely contribute to the carcinogenic potential of NASH. 
 
Fig. 3. Proposed pathogeneses of HCC in NAFLD/NASH. 
Obesity, diabetes, and insulin resistance are strongly associated with hyperinsulinemia, 
which can trigger upregulation of IGF-1, activation of IRS-1, increased FFA release, 
increased secretion of TNF-, IL-6, leptin, resistin, and NF-, and decreased production of 
adiponectin. Suppression of p53 and activation of JNK-1 result in cell proliferation and 
decreased apoptosis, which in turn result in HCC. ROS are also important in the 
pathogenesis of HCC. IGF-1, insulin growth factor-1; IRS-1, insulin receptor substrate-1; 
FFA, free fatty acid; TNF-, tumor necrosis factor-alpha; IL-6, interleukin-6; NF-, nuclear 
factor-kappa; JNK-1, Jun amino-terminal kinase-1; HCC, hepatocellular carcinoma; ROS, 
reactive oxygen species. 
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Obesity and diabetes are risk factors for NASH and CC and have been implicated in 
multiple cancers, including HCC (Bugianesi et al., 2007). Insulin resistance associated with 
obesity, metabolic syndrome, and diabetes results in increased release of FFAs from 
adipocytes, increased secretion of proinflammatory cytokines such as TNF-, increased 
secretion of interleukin-6, leptin, and resistin, and decreased secretion of adiponectin. These 
processes favor the development of hepatic steatosis and inflammation (Fig. 3) (Bugianesi et 
al., 2007, Harrison, 2006).  
Hyperinsulinemia upregulates the production of insulin-like growth factor-1 (IGF1), a 
peptide hormone that stimulates growth through cellular proliferation and inhibition of 
apoptosis (Page and Harrison, 2009, Calle and Kaaks, 2004, Ish-Shalom et al., 1997). 
Insulin also activates insulin receptor substrate-1 (IRS-1), which is involved in cytokine 
signaling pathways and has been shown to be upregulated in HCC (Tanaka et al., 1997). 
The mannose 6-phosphate/IGF2 receptor (M6P/IGF2R) is involved by regulating cell 
growth and functions as a tumor suppressor. Mutations resulting in loss of 
heterozygosity for this receptor have been detected in 61% of patients with HCC 
(Yamada et al., 1997). Adiponectin is an anti-inflammatory polypeptide specific to 
adipose tissue that is decreased in insulin-resistant states and has been shown to inhibit 
angiogenesis via modulation of apoptosis in an animal model (Ukkola and Santaniemi, 
2002, Brakenhielm et al., 2004). In an insulin-resistant state, these factors promote 
uninhibited cell growth and appear to play a significant role in the development of HCC 
in patients with NASH. 
NASH is also associated with oxidative stress and the release of reactive oxygen species 
(ROS), which likely contribute to the development of HCC. An insulin-resistant obese 
mouse model demonstrated that ROS production is increased in the mitochondria of 
hepatocytes with fatty infiltration and that oxidative stress may be implicated in hepatic 
hyperplasia (Bugianesi et al., 2007, Yang et al., 2000). During carcinogenesis, epithelial 
hyperplasia and dysplasia generally precede cancer by many years (Bugianesi et al., 
2007). C-Jun amino-terminal kinase 1 (JNK1) has also recently been linked to obesity, 
insulin resistance, NASH, and HCC. JNK1 is a ubiquitously expressed mitogen-activated 
protein kinase. Obesity is associated with abnormally elevated JNK activity (Hirosumi et 
al., 2002). In hyperinsulinemia, FFA, TNF-, and ROS are potent activators of JNK, which 
in turn phosphorylates IRS-1 (Hirosumi et al., 2002, Gomaa et al., 2008). Evidence 
suggests that statins significantly decrease the risk of HCC in diabetic patients, 
presumably because of their anti-inflammatory properties (El-Serag and Rudolph, 2007, 
Huether et al., 2005, Kawata et al., 2001, El-Serag et al., 2009). Interestingly, atorvastatin 
therapy has been shown to acutely decrease expression of JNK and other inflammatory 
cells in patients with abdominal aortic aneurysms (Kajimoto et al., 2009). That statin 
treatment reduces JNK expression may explain, in part, the decreased risk of HCC in 
diabetic patients who receive statin therapy, although this has yet to be proven. Further 
studies linking statins and JNK activity with NASH and HCC may enable the 
development of therapeutic drugs for the prevention and treatment of NASH as well as 
HCC secondary to NASH. There is a lack of randomized controlled trials on the benefits 
of bariatric surgery for patients with NASH and obese patients in terms of prevention of 
HCC (Chavez-Tapia et al., 2010). (Fig. 4) 
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Fig. 4. Proposed progression of and significant factors in the pathogenesis of HCC in NAFLD. 
ROS, reactive oxygen species; DNA, deoxyribonucleic acid; PGE2, prostaglandin type 2; 
TNF-, tumor necrosis factor-alpha 
5. Conclusion 
The most common cause of liver disease in developed countries is NAFLD, which includes 
NASH and its associated complications. The prevalence of NAFLD and NASH is likely 
higher than previously estimated and is associated with the growing epidemics of obesity 
and diabetes. There is increasing evidence showing that NASH may progress to HCC. The 
overall prevalence of HCC in patients with NAFLD remains low, although the incidence of 
HCC in developed countries is rising. HCC secondary to NASH typically develops when 
cirrhosis is present, although rare cases of HCC arising in cases of NASH without cirrhosis 
raise the possibility that carcinogenesis secondary to NAFLD can occur in the absence of 
advanced liver disease. The connection between NAFLD and progression to HCC is 
becoming clearer, and the increasing burden of NASH, diabetes mellitus, and obesity is 
becoming heavier. Community awareness of the potential for this disease to progress to 
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HCC is critical. Complications of NASH are expected to increase with the continuing 
epidemics of obesity and diabetes. Once a diagnosis of cirrhosis is made, screening for HCC 
should be pursued. Given recent epidemiological data on diabetes, thought should be given 
to the use of statins for NASH patients, particularly those with diabetes and hyperlipidemia. 
Further research is urgently needed to better elucidate the signaling pathways that result in 
HCC when insulin resistance is present. Studies evaluating potential targets for the 
treatment of NASH and HCC, including those targeting JNK activation, should be actively 
pursued. 
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